Physician profile
Alejandro Robles
NPI 1023541513
$7,442.79
in general payments reported to CMS, 2019-2025
27 companies · $2,798 in 2025
The $2,798 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.27 · 2021: $1,038 · 2022: $530 · 2023: $1,842 · 2024: $1,222 · 2025: $2,798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,008 · Travel and Lodging: $755 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,008.42 |
| Travel and Lodging | $754.63 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,100.78 | 2023-2025 | Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $999.24 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $734.17 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Madrigal Pharmaceuticals | $665.91 | 2024-2025 | Rezdiffra, Resmetirom |
| Wilson Cook Medical Incorporated | $641.67 | 2022-2023 | Fusion |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $612.90 | 2021-2025 | Xifaxan, Relistor |
| Cook Medical LLC | $510.85 | 2021-2025 | Fusion, Hemospray |
| Ardelyx, INC. | $372.99 | 2023-2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $336.36 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $240.37 | 2021 | |
| Gilead Sciences, INC. | $224.97 | 2021-2024 | |
| Ferring Pharmaceuticals INC. | $168.14 | 2023 | Rebyota |
| Enterra Medical, INC. | $160.04 | 2025 | |
| Mallinckrodt Hospital Products INC. | $138.71 | 2025 | Terlivaz |
| Ipsen Biopharmaceuticals, INC | $92.79 | 2024-2025 | Iqirvo, Bylvay |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $83.14 | 2024 | |
| Philips North America LLC | $59.41 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Olympus America INC. | $59.06 | 2025 | Evis Exera III Colonovideoscope, Gastrointestinal Videoscope |
| Intercept Pharmaceuticals, INC. | $56.48 | 2021-2023 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $46.47 | 2025 | Dupixent |
| Atricure, INC. | $24.51 | 2025 | Synergy Ablation System |
| Mirum Pharmaceuticals, INC. | $21.02 | 2025 | Chenodal, Livmarli, Cholbam |
| Medtronic, INC. | $20.77 | 2022 | |
| Boston Scientific Corporation | $20.72 | 2025 | Wallflex Duodenal |
| Phathom Pharmaceuticals, INC. | $18.00 | 2024 | Voquezna |
| Pfizer INC. | $17.24 | 2024 | |
| Adaptive Biotechnologies Corporation | $16.08 | 2025 | Clonoseq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Robles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.